

REPORTING ON AASLD 2017
**ADVANCES IN CHRONIC HEPATITIS C:
MANAGEMENT AND TREATMENT**
**COMPREHENSIVE EXPERT REVIEW AND
DISCUSSION OF KEY PRESENTATIONS**

AN INDEPENDENT CME ACTIVITY JOINTLY PROVIDED BY POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALD, INC.
THE COVERAGE IS NOT SANCTIONED BY THE CONFERENCE ORGANIZERS AND IS NOT AN OFFICIAL PART OF THE CONFERENCE PROCEEDINGS.

REPORTING ON AASLD 2017
**ADVANCES IN CHRONIC HEPATITIS C:
MANAGEMENT AND TREATMENT**
**COMPREHENSIVE EXPERT REVIEW AND
DISCUSSION OF KEY PRESENTATIONS**

AN INDEPENDENT CME ACTIVITY JOINTLY PROVIDED BY POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALD, INC.
THE COVERAGE IS NOT SANCTIONED BY THE CONFERENCE ORGANIZERS AND IS NOT AN OFFICIAL PART OF THE CONFERENCE PROCEEDINGS.

**HCV TREATMENT,
HEPATOCELLULAR CANCER AND
CLINICAL OUTCOMES**

Mark Sulkowski, MD
Professor of Medicine
Johns Hopkins University School of Medicine

REPORTING ON AASLD 2017

**ADVANCES IN CHRONIC HEPATITIS C:
MANAGEMENT AND TREATMENT**

**COMPREHENSIVE EXPERT REVIEW AND
DISCUSSION OF KEY PRESENTATIONS**

AN INDEPENDENT CME ACTIVITY JOINTLY PROVIDED BY POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALED, INC.
THE COVERAGE IS NOT SANCTIONED BY THE CONFERENCE ORGANIZERS AND IS NOT AN OFFICIAL PART OF THE CONFERENCE PROCEEDINGS.

**IMPACT OF SUSTAINED VIROLOGIC RESPONSE
WITH DIRECT-ACTING ANTIVIRAL TREATMENT ON
MORTALITY AND HEPATOCELLULAR CARCINOMA**

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole

Abstract 78

BASELINE CHARACTERISTICS

- 15,069 patients with advanced liver disease (FIB 4 >3.25)
- 41,226 patients with less advanced disease

	ACLD		Non-ACLD	
	No SVR (n=1062)	SVR (n=13,992)	No SVR (n=1308)	SVR (n=39,918)
Age (mean ± SD)	62.1±5.6	63.2±5.5	60.3±8.5	61.2±7.4
Male	98%	97%	97%	96%
African American	28%	31%	43%	38%
Caucasian	56%	55%	45%	52%
History of decompensation	35%	25%	—	—
Alcohol abuse diagnosis	30%	21%	27%	20%
Hard drug use	16%	11%	21%	14%
LDV/SOF	58%	60%	64%	65%
Albumin g/dL (mean±SD)	3.4±0.6	3.6±0.5	3.9±0.4	4.0±0.4
Platelets K/uL (mean±SD)	105±40	116±42	220±57	220±60
Mean follow-up (days)	542±224	595±217	458±218	499±233


INCIDENT HCC RATES IN ACLD

G	No SVR (N=871)		SVR (N=13,153)		Reduction
	HCC n	HCC/100 PY (95% CI)	HCC N	HCC/100 PY (95% CI)	
1a	74	11.0 (8.6–13.8)	214	1.6 (1.4–1.9)	85.5%
1b	14	8.5 (4.7–14.3)	115	2.3 (1.9–2.8)	72.9%
2	21	13.7 (8.5–21.0)	34	2.0 (1.4–2.8)	85.4%
3	31	14.7 (10.0–20.9)	31	2.6 (1.8–3.6)	82.3%
TOTAL	140	11.5 (9.7–13.6)	397	1.9 (1.7–2.1)	83.5%
TOTAL	1-year HCC	1-year HCC rate (95% CI)	1-year HCC	1-year HCC rate (95% CI)	Reduction
	67	9.4% (7.4–11.9)	210	1.9% (1.7–2.2)	79.8%


Belperio PS, et al. AASLD 2017, Washington DC. #78

IMPACT OF SVR WITH DAA TREATMENT ON MORTALITY AND HCC

K-M Curves for ACLD Deaths and HCC




K-M Curves for Non-ACLD



Belperio P, et al. 68th AASLD, Washington, DC, October 20-24, 2017; Abst. 78.

DEVELOPMENT AND VALIDATION OF MODELS PREDICTING THE RISK OF HCC AFTER ANTIVIRAL TREATMENT FOR HCV


- Massive cohort from VA
- Cox proportional hazards regression, with data splitting



- A model for probability of HCC was developed (Available on-line soon)

Ioannou G, et al. 68th AASLD; Washington, DC; October 20-24, 2017; Abst. 73.

RESULTS



Ioannou G, et al. 68th AASLD; Washington, DC; October 20-24, 2017; Abst. 73.